Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review

Author(s): Douglas R. Abdalla, Cindy Simoens, John-Paul Bogers, Eddie F.C. Murta, Marcia A. Michelin

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 10 , Issue 3 , 2015

Become EABM
Become Reviewer


The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.

Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [298 - 307]
Pages: 10
DOI: 10.2174/1574892810999150827153642
Price: $65

Article Metrics

PDF: 42